热点聚焦！开心麻花贺岁大戏《这家伙不赖》首演 常远自导自演笑料十足

开心麻花贺岁大戏《这家伙不赖》首演 常远自导自演笑料十足

北京 - 由开心麻花知名演员常远领衔主演并身兼导演与编剧的喜剧作品《这家伙不赖》，于2024年12月22日在北京海淀剧院拉开帷幕。该剧首演当天，现场气氛热烈，火爆非凡，演出中更是笑声不断，赢得了观众和媒体的一致好评。

《这家伙不赖》讲述了知名老赖刘惜金受小山村村民跳跳委托，前往东卡尼亚向欠下村民三千万的黄大发讨债的故事。在巨大的利益面前，刘惜金因动摇导致任务失败，为弥补过失，他再次踏上征途，势要讨回这一切。在与黄大发、正义组织反赖行动组的三方缠斗中，这趟啼笑皆非的旅程将如何收场，刘惜金又将何去何从？

该剧以独特的喜剧风格、精湛的演技和富有深度的剧情，展现了小人物在大时代中追求梦想、坚守正义的励志故事。常远在剧中饰演的刘惜金，将一个既老赖又善良的小人物演绎得活灵活现，引发了观众的强烈共鸣。

除了常远之外，该剧还集结了宋阳、黄才伦、杨沅翰等众多开心麻花功勋演员。他们在舞台上的精彩表现，也为观众带来了不少欢乐。

舞美置景方面，该剧也颇费心思。以高水准设计最大程度展现不同地域风情，致力于带来强烈的观剧沉浸感与视觉冲击。

《这家伙不赖》是开心麻花今年贺岁档的重磅作品，也是常远导演生涯的处女作。该剧的成功上演，不仅为观众带来了欢乐，也为开心麻花的贺岁喜剧又添上了浓墨重彩的一笔。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.